Precision Business Insights
Portfolio

 

Research Reports

Sleep Aids Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Sleep Aids Market: By Product Type (Medication, Sleep Apnea Devices, Mattresses and Pillows, Others), By Application (Insomnia, Narcolepsy, Restless Legs Syndrome, Sleep Apnea, Sleep Walking, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Others), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global sleep aids market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

 

Market Outline: Sleep Aids Market

Sleep aids includes medical devices, drugs which enables induce sleep in patients with various sleep related disorders. The sleeping aids help in diagnosis and treatment of sleep disorders. Sleeping disorder affect the ability of individuals sleeping capacities. Most of the people undergo sleeping issues owing to stress and hectic schedules. A proper sleep is the one with no interruptions, which allows the body to experience natural sleep cycle. Sleep could be affected by various factors such as time taken to fall asleep, alcohol consumption prior to sleep, and duration of sleep. While some are caused owing to hereditary factors. The sleeping disorder leads to several chronic diseases such as diabetes, obesity and cardiovascular diseases.

Market Dynamics: Sleep Aids Market

Burgeoning the prevalence of sleep disorders is expected to drive the growth of sleep aids market. According to Centers for Disease Control and Prevention (CDC), around 49.2 million people with sleeping disorder in the year 2017. The increasing use of the caffeine, tobacco and alcoholic products is expected to enhance the growth of sleep aids market. The stressful lifestyle, high work pressures is expected to fuel the growth of market. However, the side effects associated with the intake of the sleeping pills on regular basis is anticipated to hamper the growth of sleeping aids market. The patent expiration of several drugs related with sleeping disorder is dampen the growth of sleep aids market.

Market Scope: Sleep Aids Market

Sleep aids market is segmented based on the product type, application, and distribution channel

Based on the product type, the market is segmented into the following:

  • Medication
    • Herbal Drugs
    • Prescription-based Drugs
    • Over-the-counter Drugs
  • Sleep Apnea Devices
  • Mattresses and Pillows
  • Others

Based on the applications, the market is segmented into the following:

  • Insomnia
  • Narcolepsy
  • Restless Legs Syndrome
  • Sleep Apnea
  • Sleep Walking
  • Others

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Regional Analysis:  Sleep Aids Market

Geographically, global sleep aids market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America sleep aids market is anticipated to expand at unprecedented growth rates due to increase in the prevalence of sleeping disorders, followed by Europe and Asia Pacific.  According to the American Academy of Sleep Medicine, approximately 25 million people experienced sleep apnea disorder in the U.S. in 2014. The Asia Pacific sleep aids market is expected to grow at significant CAGR in forecasted period. As per Food and Drug Administration (FDA), around 339 million sleeping pills that were sold in the Japan.

Competition Assessment: Sleep Aids Market

Some of the players in the global sleep aids market include:

  • Merck & Co. (U.S)
  • Cadwell (U.S)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Care Fusion Corporation (U.S)
  • Natus Medical Incorporated (U.S)
  • Compumedics Limited. (Australia)

Notable Market Developments: Sleep Aids Market

  • In February 2015, Merck known as MSD outside the United States and Canada, announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Merck & Co. (U.S)
  • Cadwell (U.S)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Care Fusion Corporation (U.S)
  • Natus Medical Incorporated (U.S)
  • Compumedics Limited. (Australia)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

$ 3,000.00$ 8,900.00
Clear selection

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials